Renessa(R) Treatment for Female Incontinence Named Most Promising New Product

Award Presented at Phoenix Conference of Medical Device CEOs

NEWARK, Calif., Oct. 13 /PRNewswire/ -- Novasys Medical, Inc., a developer of
innovative therapies in women's health, announced today that its Renessa®
non-surgical treatment for female stress urinary incontinence (SUI) was
inducted into the Phoenix Hall of Fame as the 2009 Most Promising New Product
at the Phoenix Medical Device and Diagnostic Conference for Chief Executive
Officers. The Phoenix Awards are presented for outstanding achievement in the
medical device and diagnostic industry to individuals and companies selected
by industry CEOs.

"Everyone at Novasys is deeply honored by this award, particularly since we
were chosen by leaders in our industry," said Debra Reisenthel, Novasys
President and Chief Executive Officer. "They know our non-surgical Renessa
treatment offers women afflicted with stress urinary incontinence an
opportunity to resume activities that make their lives fulfilling."

Attorney J. Casey McGlynn who is a partner with Wilson Sonsini Goodrich &
Rosati and co-founder of the Phoenix Conference, commented, "Novasys' Renessa
System joins an elite group of past award winners. That prestigious list
includes large and small companies with groundbreaking technologies that
changed the standard of medical care, including Conceptus' Essure device,
JNJ/Cordis' drug eluting stent, and Boston Scientific's (Guidant's)
implantable defibrillators."

Beckie Robertson, Managing Director with Versant Ventures and another founder
of the Phoenix Conference, remarked, "The non-surgical Renessa treatment
represents a true breakthrough in therapeutic options for stress urinary
incontinence. Before this safe, effective, in-office treatment was available,
women who failed conservative therapies such as Kegel exercises, and couldn't
accept surgical risks or a long recovery, had very few options."

Female Stress Urinary Incontinence (SUI)
SUI is the involuntary leakage of urine associated with coughing, sneezing,
laughing and recreational activities. It is caused by a variety of factors -
most commonly childbirth - and often restricts the social, professional, and
personal lives of an estimated 15 million women in the U.S. alone. With
currently available surgical and non-surgical SUI therapies, many patients and
physicians have concerns about safety, recovery, compliance and/or
effectiveness. Experts estimate 80% of women with SUI thus do not seek
treatment of any kind.

The FDA-cleared Renessa System includes a small probe which a physician passes
through the natural opening of the urethra (transurethral). The probe gently
heats the tissue in the bladder neck and upper urethra. The heat denatures the
collagen in the tissue, and upon healing, the tissue becomes firmer and more
resistant to leaks. The Renessa treatment can be performed in the convenience
of a physician's office, or in an outpatient setting, using local anesthesia.
There are no incisions, bandages or dressings required. Recovery is rapid and
comfortable, with minimal post-procedure limitations.

More than 350 urologists, urogynecologists and gynecologists have been trained
and have performed the Renessa procedure in nearly 3,000 patients.

About Novasys Medical
Novasys Medical, Inc. is a privately held, venture-backed company which
develops innovative therapies in women's health. The company's initial focus
is the development and commercialization of the Renessa System, a proprietary,
non-surgical approach to the treatment of female stress urinary incontinence
(SUI).

For more information, please visit www.novasysmedical.com or call (510)
226-4060.

SOURCE Novasys Medical, Inc.

Lauri Campbell of Novasys Medical, +1-510-226-4060